Medical Affairs Platform
Medical grantmaking software for life sciences companies
Bonterra CyberGrants makes it faster and easier for you to process approvals for expanded access, medical education, and research grants programs.

Build customized workflows
Streamline grant review and approvals with automated, tailored workflows and role-based user permissions.

Ensure compliance and reduce risk
Our flexible data enables teams to collect the info they need to make informed, fast grantmaking decisions and ensure robust audit trails for compliance and regulatory teams.

Create a central information hub
Every grant, across every country, feeds into one unified data system — your single source of truth for outcomes, budgets, and milestone updates.

Simplify complex processes
Our team will help you scale back application questions, approval steps, and users involved for peak efficiency.
Bonterra products for life sciences companies
Explore the core Bonterra solutions that power medical grantmaking.
Solving key medical grantmaking challenges
Our system mitigates common challenges for life sciences companies, making the grant lifecycle efficient and impactful.
Bonterra CyberGrants created a one-stop location where we can easily view every step of the process and centrally manage all of our data.
FAQs about our medical grantmaking software
No, our medical grantmaking software is not a constituent relationship management (CRM) platform. Rather, our best-in-class grants management solution focuses on streamlining the funding process for life sciences companies.
Insights and resources for leading life sciences companies
One configurable platform for every medical affairs grantmaking program
Medical affairs teams are under increasing pressure to support scientific engagement, accelerate patient access, and demonstrate program value—all while navigating complex compliance requirements. Yet many organizations still rely on fragmented systems, manual workflows, and disconnected processes that make it difficult to scale efficiently. This executive brief explores how leading life sciences organizations are replacing legacy […]